The $35 Billion Problem Between Diagnosis and Treatment

In American healthcare, one of the most frustrating bottlenecks sits between the moment a doctor prescribes a medication and the moment a patient actually receives it. Prior authorization—the process of getting insurer approval before treatment—costs the U.S. healthcare system an estimated $35 billion annually in administrative spending. Over 53 million prior authorization requests flood Medicare Advantage insurers alone each year, with 7.7% denied outright. The kicker? When denials are appealed, 81.7% get fully or partially overturned, revealing a system that delays care more often than it prevents waste.

Latent Health just raised $80 million in Series A funding to take on this problem with clinical AI. Co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator, the round is one of the most significant healthcare AI raises of 2026—and more than three times the average Series A for AI healthcare startups.

From Stanford AI Lab to Healthcare's Core Infrastructure

Latent Health was co-founded in 2022 by Sriram Somasundaram and Rishabh Jain, two Indian-American entrepreneurs who brought complementary skill sets to the table.

Somasundaram is a Stanford-trained AI researcher whose academic work spanned molecular binding patterns in adaptive immunity and deep reinforcement learning robotics, resulting in publications at ICML, ICLR, and Nature. He worked at the Stanford Artificial Intelligence Laboratory (SAIL) before joining Hebbia as a founding team member, where he operationalized language models for major financial institutions. He also spent time as a software engineer at Riot Games.

Jain is a serial entrepreneur who previously bootstrapped a company and sold it for an eight-figure sum. His strength lies in building and scaling businesses from zero—a critical complement to Somasundaram's deep technical expertise.

The pair went through Y Combinator's Winter 2023 batch and set out to build what Somasundaram describes as "the intelligence infrastructure for American healthcare." Their vision: ensure that no patient waits unnecessarily between receiving a diagnosis and starting treatment.

The Clinical Reasoning Engine: Beyond Simple Automation

At the core of Latent Health's platform is its Clinical Reasoning Engine—a system that goes far beyond robotic process automation or simple form-filling. The engine performs actual clinical knowledge work:

• Reads and reasons through patient data from electronic health records (EHRs)
• Interprets drug criteria against payer guidelines and formulary requirements
• Extracts clinical evidence needed to support medication approval
• Orchestrates workflows across hospitals, payers, pharmacies, and patients

The distinction matters. While many healthcare AI tools automate individual tasks—transcription, coding, billing—Latent Health operates at the clinical reasoning layer, making judgments about whether a patient meets criteria for a specific therapy and assembling the evidence to prove it. This is work traditionally done by specialized nurses and pharmacists spending hours on phone calls and faxes.

The results speak for themselves: Latent reports denial rates reduced by more than 30% and clinicians able to serve twice as many patients through its platform.

$80M Series A: Breaking Healthcare AI Benchmarks

The $80 million raise is exceptional by any measure. In 2025, AI-enabled digital health startups averaged $24 million for Series A rounds—already a 56% premium over non-AI companies. Latent Health's round sits at 3.3x that benchmark, signaling extraordinary investor conviction.

The investor syndicate tells a strategic story:

• Spark Capital (co-lead): The top-tier firm is raising a $3 billion fund in 2026 and has been increasingly active in healthcare AI, with recent investments including Profluent (AI protein design) and Headway (mental healthcare).
• Transformation Capital (co-lead): A healthcare-specialist growth investor with deep sector expertise and relationships.
• McKesson Ventures: Perhaps the most strategically significant participant. McKesson is America's largest pharmaceutical distributor, and its venture arm invests in only ~2 companies per year. Their involvement signals potential supply chain integration opportunities.
• General Catalyst: A mega-fund with an expanding healthcare portfolio and a unique model of directly operating health systems.
• Conviction: An AI-focused venture firm that validates the technical depth of Latent's approach.
• Y Combinator: Continued backing post-batch signals sustained confidence in the founding team.

Market Context: A Massive Services-to-Software Conversion

The timing of this raise aligns with powerful tailwinds in healthcare AI investing. In 2025, U.S. digital health startups raised $14.2 billion—the highest since 2022—with AI companies capturing 54% of total funding. AI-enabled startups commanded an 83% premium in average round size compared to non-AI peers.

But the prior authorization market specifically is where the opportunity gets compelling. The broader healthcare administrative market represents $98 billion in annual spending, yet only 3% is currently addressed by software. Prior authorization AI spending alone grew 10x year-over-year, from $10 million in 2024 to $100 million in 2025.

The competitive landscape is heating up:

• Tandem AI reached unicorn status in 2026 with its AI prescription platform
• SamaCare processed over $6.2 billion in specialty medication prior authorizations, improving patient access by 40-90%
• Anterior integrated clinical AI into HealthEdge's utilization management platform
• Interra Health (DoseSpot + Arrive Health merger) offers e-prescribing and medication pricing networks

Latent Health differentiates by operating at the clinical reasoning layer rather than the administrative automation layer. While competitors may automate form submission, Latent's engine understands why a patient needs a medication and builds the clinical case accordingly—directly within the EHR workflow.

From 4 to 45+ Health Systems in One Year

The growth numbers are what make this story remarkable. In the past year, Latent Health expanded from 4 to more than 45 health system partners, now serving 50% of the top 20 U.S. health systems. The customer list reads like a who's who of American academic medicine:

• Yale New Haven Health
• Ochsner Health
• Vanderbilt Health
• Mount Sinai Health System
• UCSF Health
• UCLA Health
• Henry Ford Health System
• MetroHealth
• UCI

More than 2 million patients are already accessing medications faster through the platform. For a Series A company with approximately 50 employees, this level of enterprise penetration is extraordinary and suggests strong product-market fit validated at scale.

What They'll Do With the Money

Latent Health plans to deploy the $80 million across several strategic priorities:

Expanding the health system footprint beyond 45 partners toward national coverage. With half of the top 20 systems already on board, the playbook for enterprise sales is clearly working.

Deepening the platform's network effects by connecting more stakeholders—hospitals, payers, pharmacies, and patients—into a unified workflow. This is where the McKesson Ventures investment becomes particularly relevant, as McKesson's pharmaceutical distribution network could provide a natural integration pathway.

Investing in reliability and trust infrastructure, which is essential for clinical AI tools where errors can directly impact patient care. The 2026 healthcare AI landscape increasingly rewards companies that can demonstrate not just capability but consistent, trustworthy performance in production environments.

Scaling the team from its current ~50 employees to support the growing customer base and product roadmap.

Why Investors Are Betting Big

The investor thesis here rests on three pillars. First, the problem is enormous and clearly defined: $35 billion in annual administrative waste, millions of patients waiting for medications, and an 81.7% appeal overturn rate that proves most denials shouldn't happen in the first place.

Second, product-market fit is proven at enterprise scale. Going from 4 to 45+ health systems in a year—including names like Yale, Vanderbilt, and UCLA—isn't a pilot story. It's a deployment story. The 2026 healthcare VC consensus is to back companies that have moved from pilot to production, and Latent Health embodies that thesis.

Third, the network dynamics are compelling. Every new health system that joins creates more clinical data flowing through the reasoning engine, making it smarter. Every payer integration reduces friction for all connected providers. This is a platform that gets more valuable as it scales—the classic venture flywheel.

What to Watch

Latent Health's $80M Series A marks a defining moment in the clinical AI space. The company has demonstrated that AI can move beyond ambient scribes and coding tools into the core clinical workflow of getting patients their medications. The key questions going forward: How quickly can they expand beyond 45 health systems to achieve true national coverage? Can they build the payer-side network to complement their provider relationships? And critically, as the platform processes more patient journeys, can the Clinical Reasoning Engine maintain the accuracy and reliability that earned it the trust of America's top health systems? In a healthcare AI market increasingly bifurcating between hype and impact, Latent Health is firmly planting its flag on the impact side.